Archive 2018

2018

• - Destiny Pharma notes Daily Telegraph coverage on antibiotic resistance
• - Destiny Pharma announces research collaboration with the University of Southampton targeting infections in diabetic foot ulcers and cystic fibrosis
• - Directorate Change
• - Destiny Pharma to attend 2018 BioInfect Conference, November 8th 2018, Cheshire, UK
• - UK government highlights global threat of AMR
• - BIA celebrates UK bioscience innovative
• - Destiny Pharma to attend Biotech Showcase, January 7th – 9th 2019, San Francisco, USA
• - Destiny Pharma to attend BioJapan, 10-12 October 2018, Pacifico Yokohama, Japan
• - Destiny Pharma announces appointment of Chief Medical Officer
• - Interim results for the 6 months ended 30 June 2018
• - Destiny Pharma to attend CPhI, 9-11 October 2018, Feria de Madrid, Spain
• - Directorate Change
• - 26 Jul 2018 – Destiny Pharma announces positive data from XF-73 Phase 1 skin irritation study
• - 17 Jul 2018 – Research collaboration with Aston University to investigate new XF-platform drug candidates
• - Destiny Pharma to attend ID Week, 3-7 October 2018, in San Francisco, USA
• - Destiny Pharma to present at Shares Investor Event, 10th July 2018, in London, UK
• - 03 Jul 2018 – Destiny Pharma welcomes significant PULL incentive
• - 14 Jun 2018 – Destiny Pharma notes FDA statement on their focus to enable new approaches to fight AMR
• - 30 May 2018 – Scientific Advisory Board
• - Destiny Pharma to attend Bio-Europe 2018, 5th – 7th November 2018, in Copenhagen, Denmark
• - Destiny Pharma to attend ASM Microbe 2018, 7th – 11th June 2018, in Atlanta, USA
• - Destiny Pharma to speak at the second meeting of the UK BioIndustry Association’s China Special Interest Group in London on 2nd May 2018
• - 23 Apr 2018 – Posting of Accounts and Notice of AGM
• - 12 Apr 2018 – Clinical update
• - 12 Apr 2018 – Audited results for the year ended 31 December 2017
• - Destiny Pharma attending International Conference on Porphyrins and Phthalocyanines (ICPP) in Munich, Germany from 1st – 6th July 2018
• - 22 Mar 2018 – Cost of antibiotic-resistant infections in U.S. tops $2B per year
• - 23 Mar 2018 – Destiny Pharma to announce financial results for the year ended 31 December 2017 on Thursday 12 April 2018
• - 22 Mar 2018 – Appointment of Joint Broker
• - 15 Mar 2018 – Destiny Pharma announces FDA Fast Track Designation for lead clinical candidate, exeporfinium chloride (XF-73)
• - Destiny Pharma attending ECCMID 2018 in Madrid, Spain from 21st – 24th April 2018
• - Destiny Pharma attending Superbugs and Superdrugs 2018 in London from 19th – 20th March 2018
• - 02 Feb 2018 – Destiny Pharma opens IND for its novel anti-infective drug XF-73 ahead of commencing US clinical trials
• - Destiny Pharma attending the 11th Berlin Conference on Life Sciences – Novel Antimicrobials and AMR Diagnostics on 2 March 2018
• - Destiny Pharma attending BioEurope Spring 2018 in Amsterdam from 12th – 14th March 2018
• - Destiny Pharma presenting at the Guinness AIM Investor Seminar in London on 22nd February 2018
• - 05 Feb 2018 – Destiny Pharma wins Deal of the Year at the Insider South East Dealmaker Awards 2018
• - 29 Jan 2018 – $1bn rewards proposed at Davos 2018 for new antibiotics
• - Destiny Pharma attending the Biotech and Money World Congress in London on 5th–6th February 2018
• - 09 Jan 2018 – Equity Development initiates coverage of Destiny Pharma

Archive

2019

2018

2017

2016

2015